R56.1 Insurance Policy Changes

ICD-10 R56.1 is officially defined as "Post traumatic seizures." code R56.1 is referenced in 11 tracked payer policy changes from Aetna and Blue Cross & Blue Shield of Mississippi. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code R56.1 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Oct 27, 2026Medium impact
Selected Techniques for Delivery of Drugs to the Brain (CPB 0731, reviewed 2026-10-21)
Aetna Clinical Policy Bulletin 0731 (last review 10/21/2026) states that convection-enhanced delivery of drugs into brain parenchyma and low-intensity MR-guided focused ultrasound mediated disruption of the blood-brain barrier for drug delivery are experimental, investigational, or unproven because their safety and effectiveness have not been established. The policy lists CPT 0947T and several ICD-10 codes, including those for malignant neoplasm of brain, Alzheimer's disease, and epilepsy, as not covered for the indications listed in the bulletin.
Aetna · Identified Aug 17, 2026Medium impact
Quantitative, Functional and Connectomic Analysis of Brain MRI (CPB 0739, reviewed 2026-07-24)
Aetna considers functional MRI (fMRI) medically necessary to identify the eloquent cortex in pre-surgical evaluation of persons with brain tumors (except temporal tumors), epilepsy (except temporal neocortical epilepsy), or vascular malformations. Aetna considers connectomic analysis of multi-modal brain MRI and automated quantification of brain MRI experimental, investigational or unproven, and considers fMRI experimental, investigational or unproven for identifying the eloquent cortex in temporal neocortical epilepsy or temporal tumors and for the diagnosis, monitoring, prognosis, or surgical management of all other listed indications, including Alzheimer's disease, migraines, multiple sclerosis, schizophrenia and autism spectrum disorder. CPT 70554 and 70555 are covered if the selection criteria are met, while CPT 0865T, 0866T and 1039T are not covered for the indications listed in the policy.
Aetna · Identified Aug 17, 2026Medium impact
Fetal Echocardiography and Magnetocardiography (CPB 0106, reviewed 2026-03-26)
Aetna considers fetal echocardiograms, Doppler and color flow mapping after 12 weeks gestation medically necessary for listed indications. These include a mother with type 1 diabetes or pregestational type 2 diabetes on insulin during the first trimester, a mother with systemic lupus erythematosus, a fetal nuchal translucency of 3.5 mm or greater in the first trimester, pregnancies conceived by IVF or ICSI, monochorionic twins, suspected twin-twin transfusion syndrome, suspected or documented fetal arrhythmia, suspected or known fetal chromosomal abnormalities, single umbilical artery, persistent right umbilical vein, non-immune fetal hydrops or unexplained severe polyhydramnios, and seizure disorders in members even if they are not taking anti-seizure medication. Fetal exposure to anti-seizure medications, excessive alcohol, lithium, paroxetine or retinoids is also a listed indication. Repeat studies are covered for listed findings and for fetal surveillance of anti-Ro (SSA) or anti-La (SSB) exposure, which may be repeated every 1 to 2 weeks starting at 16 weeks gestation through 28 weeks, then every other week until 32 weeks. Fetal echocardiograms for advanced maternal age screening, gestational diabetes even if requiring insulin after the first trimester, modafinil exposure, selective serotonin reuptake inhibitors except paroxetine, tacrolimus, a tortuous ductus arteriosus, and suspected cystic fibrosis are experimental, investigational or unproven. Fetal magnetocardiography and deep learning-based models for diagnosing fetal arrhythmia are also experimental, investigational or unproven.
Aetna · Identified Aug 17, 2026Medium impact
Stereotactic Radiosurgery (CPB 0083, reviewed 2026-03-11)
Aetna considers stereotactic radiosurgery (SRS) medically necessary in certain circumstances, and refers to the eviCore Healthcare Radiation Therapy Clinical Guidelines for medical necessity criteria. Cranial SRS is medically necessary for benign brain and spinal tumors, cranial arteriovenous malformations, cavernous malformations and hemangiomas, trigeminal neuralgia that has not responded to more conservative treatments, severe essential tremor not adequately responsive to standard medical therapy, disabling tremor in Parkinson's disease for patients who meet thalamotomy criteria but are not surgical candidates, and primary brain tumors and primary or secondary tumors involving the spine. For brain metastases, SRS is considered appropriate with a Karnofsky Performance Status of 40 or greater (or expected to return to 70 or greater), or an ECOG status of 3 or less (or expected to return to 2 or less), fewer than 10 metastatic lesions, and control of or expected control of extracranial disease. Stereotactic body radiation therapy is medically necessary for liver or hepatobiliary cancer stage I to II, organ-confined prostate cancer, inoperable stage I or IIA lung cancer, unresectable stage I to III pancreatic cancer, recurrent disease requiring re-irradiation, and oligometastatic breast, non-small cell lung, colorectal, renal cell, prostate, sarcoma, melanoma and head and neck cancers with 1 to 5 total metastases, and Aetna considers SRS experimental, investigational, or unproven for cluster headaches, epilepsy (except when associated with treatment of arteriovenous malformations or brain tumors), and mammographic microcalcification.
Aetna · Identified Aug 16, 2026Medium impact
Grid Monitoring and Intraoperative Electroencephalography (CPB 0289, reviewed 2026-04-17)
Aetna considers intraoperative scalp EEG medically necessary for monitoring cerebral function during carotid artery surgery, during intracranial vascular surgical procedures, and during parietal tumor resection or resection of a lesion near the eloquent cortex. Grid monitoring (electrocorticography) to determine the location of the epileptogenic focus for possible surgical resection is medically necessary for members with intractable seizures when seizures arise from functionally important brain areas, when surface EEG did not adequately localize the epileptogenic area, or when electrophysiological localization is discordant with other neurodiagnostic studies suggesting an abnormality in more than one region of the brain. EEG monitoring during WADA testing is medically necessary, while intraoperative EEG for open-heart surgery and grid monitoring for all other indications not listed are experimental, investigational, or unproven.
Aetna · Identified Aug 16, 2026Medium impact
Selected Techniques for Delivery of Drugs to the Brain (CPB 0731, reviewed 2025-11-26)
Aetna considers convection-enhanced delivery of drugs into the brain parenchyma experimental, investigational, or unproven. Aetna also considers low-intensity MR-guided focused ultrasound (MRgFUS) mediated disruption of the blood-brain barrier for enhanced drug delivery into the brain experimental, because the safety and effectiveness of these approaches have not been established. CPT code 0947T for MRgFUS stereotactic blood-brain barrier disruption is not covered for the indications listed, and ICD-10 codes for brain malignancies, Alzheimer's disease, epilepsy and seizures are listed as not covered.
Aetna · Identified Aug 15, 2026Medium impact
Quantitative EEG (Brain Mapping) (CPB 0221, reviewed 2026-04-14)
Aetna considers quantitative EEG (brain mapping, also called BEAM) medically necessary only as an adjunct to traditional EEG for specified uses, including ambulatory EEG recording to facilitate later expert visual interpretation, continuous EEG monitoring by frequency-trending in the operating room or ICU, and topographic voltage and dipole analysis in pre-surgical evaluations for intractable epilepsy. Aetna considers quantitative EEG experimental, investigational or unproven for all other indications, including attention disorders, autism spectrum disorders, depression, schizophrenia, bipolar disorder, insomnia, fibromyalgia, post-traumatic stress disorder and post-concussion syndrome. The BrainScope One System (Ahead 300) is considered experimental, investigational or unproven for evaluation of concussion or traumatic brain injury.
Aetna · Identified Aug 14, 2026Medium impact
Attended Electroencephalographic (EEG) Video Monitoring (CPB 0322, reviewed 2026-06-08)
Aetna considers attended electroencephalographic (EEG) video monitoring performed in a healthcare facility medically necessary when diagnosis remains uncertain after neurological examinations and standard EEG studies within the past 90 days, non-neurological causes such as syncope or cardiac arrhythmias have been ruled out, and documentation shows that extended ambulatory EEG monitoring as an outpatient would not be sufficient for the member's needs. Covered indications include differentiating epileptic events from psychogenic seizures, establishing the specific type of epilepsy in poorly characterized seizure types, establishing the diagnosis of epilepsy and evaluating response to treatment in children 3 years of age or younger, children with severe cognitive deficits, and older persons unable to communicate due to disability, evaluating newborns with proven or suspected acute brain injury and co-morbid encephalopathy, and identifying a seizure focus in members with intractable epilepsy who are being considered for epilepsy surgery. Monitoring longer than 7 days is medically necessary when events are so infrequent that they would likely not be detected within one week, when an extended stay is needed for care of an adverse event, or when medication adjustments require ongoing monitoring that cannot be safely performed on an outpatient basis. Once the cause of seizures and the specific type of epilepsy have been established, continued video EEG monitoring in older children and adults is considered not medically necessary. Attended EEG video monitoring for medical clearance to operate a motor vehicle is not considered medically necessary, and it is considered experimental, investigational or unproven for other indications including obstructive sleep apnea, assessment of the effectiveness of drug treatment in epilepsies, amyotrophic lateral sclerosis, cardiac arrest, chronic fatigue, coma, diagnosis of brain death, encephalopathy and headache.
Aetna · Identified Aug 14, 2026Medium impact
Single Photon Emission Computed Tomography (SPECT) (CPB 0376, reviewed 2026-05-28)
Aetna's Clinical Policy Bulletin 0376 sets the coverage rules for single photon emission computed tomography (SPECT). Non-cardiac SPECT is considered medically necessary for a list of indications, including osteomyelitis, distinguishing bone from soft tissue infection, pulmonary embolism by SPECT ventilation/perfusion scintigraphy, distinguishing Parkinson's disease from essential tremor using DaTSCAN, localization of abscesses, lymphoma and necrosis differentiation, neuroendocrine tumor diagnosis and staging, presurgical ictal detection of seizure focus in epilepsy in place of PET, and thyroid cancer iodine imaging. SPECT for coronary artery disease diagnosis and prognosis is considered medically necessary, except as outlined in the policy's exclusion criteria. SPECT for a list of other uses, including Alzheimer's disease and dementia, attention deficit/hyperactivity disorder, autism, schizophrenia, stroke, and absolute quantitation of myocardial blood flow, is considered experimental, investigational or unproven.
Aetna · Identified Aug 12, 2026Medium impact
Ambulatory Electroencephalography (CPB 0425, reviewed 2026-07-07)
Aetna considers ambulatory EEG, with or without home video monitoring, medically necessary to classify seizure type in members with epilepsy when routine EEG is equivocal, to diagnose a seizure disorder when history, examination and routine EEG do not resolve the diagnostic uncertainty, and to localize the epileptogenic region during pre-surgical evaluation. These indications apply where the member has had a neurologic examination and standard EEG studies within the past 12 months. Combined ambulatory EEG and home-video recording is considered an equally acceptable alternative to ambulatory EEG alone, while ambulatory EEG for all other indications and implantable sub-scalp continuous EEG systems such as Epios and Minder for managing epilepsy are considered experimental, investigational or unproven.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Vagus Nerve Stimulation
Vagus nerve stimulation is considered medically necessary as a treatment of medically refractory seizures, defined as seizures that occur despite therapeutic levels of antiepileptic drugs, or seizures that cannot be treated with therapeutic levels of antiepileptic drugs because of intolerable adverse events of these drugs. It is considered investigational for depression, heart failure, upper-limb impairment due to stroke, essential tremor, headaches, rheumatoid arthritis, fibromyalgia, tinnitus and traumatic brain injury, including but not limited to these conditions, and transcutaneous (nonimplantable) vagus nerve stimulation devices are investigational for all indications. The 05/21/2026 update changed the policy statement to say vagus nerve stimulation is considered investigational as a treatment of rheumatoid arthritis, and removed ICD-9 procedure and diagnosis codes from the code reference.

Watch R56.1

Get one email when a payer policy names R56.1, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code R56.1?

There are 11 tracked policy changes affecting code R56.1, including updates from Aetna, Blue Cross & Blue Shield of Mississippi. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code R56.1?

Payers that have issued tracked updates for code R56.1 include: Aetna, Blue Cross & Blue Shield of Mississippi.

How do I get notified when code R56.1 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code R56.1. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code R56.1?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Selected Techniques for Delivery of Drugs to the Brain (CPB 0731, reviewed 2026-10-21)

Quantitative, Functional and Connectomic Analysis of Brain MRI (CPB 0739, reviewed 2026-07-24)

Fetal Echocardiography and Magnetocardiography (CPB 0106, reviewed 2026-03-26)

Stereotactic Radiosurgery (CPB 0083, reviewed 2026-03-11)

Grid Monitoring and Intraoperative Electroencephalography (CPB 0289, reviewed 2026-04-17)

Selected Techniques for Delivery of Drugs to the Brain (CPB 0731, reviewed 2025-11-26)

Quantitative EEG (Brain Mapping) (CPB 0221, reviewed 2026-04-14)

Attended Electroencephalographic (EEG) Video Monitoring (CPB 0322, reviewed 2026-06-08)

Single Photon Emission Computed Tomography (SPECT) (CPB 0376, reviewed 2026-05-28)

Ambulatory Electroencephalography (CPB 0425, reviewed 2026-07-07)

Vagus Nerve Stimulation

What insurance policy changes affect code R56.1?

Which payers have updated policy for code R56.1?

How do I get notified when code R56.1 policy changes?

Why do payers change policies for code R56.1?